Related Experiment Video

Updated: Jun 15, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.0K

Epidermolysis Bullosa Pruriginosa Treated With Upadacitinib

Zeqiao Zhang1, Zhimiao Lin1

  • 1Dermatology Hospital, Southern Medical University, Guangzhou, China.

JAMA Dermatology
|August 21, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.5K
A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

263

Related Experiment Videos

Last Updated: Jun 15, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.0K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.5K
A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

263

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

415
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
415

Articles linked to this work by shared authors, journal, and citation graph.

Loss-of-function variants in EPHX3 cause nonsyndromic epidermal differentiation disorders.

The British journal of dermatology·2026

Mutation Analysis in Ten Cases With PNPLA1-Nonsyndromic Epidermal Differentiation Disorder: Evidence of a Founder Effect.

The Journal of dermatology·2026

Landscape of Somatic Mutations in a Large Cohort of Chinese Patients With Immune Dysregulations.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Biallelic GLTP mutations cause nonsyndromic epidermal differentiation disorder via disrupted epidermal glucosylceramide transport.

The Journal of clinical investigation·2026

De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans.

JAMA dermatology·2026

Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6-11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial.

The British journal of dermatology·2025

Global Disparities in Access to Dermatological Care.

JAMA dermatology·2026

Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.

JAMA dermatology·2026

AI-Assisted Line-Field Confocal Optical Coherence Tomography to Detect Subclinical Basal Cell Carcinoma.

JAMA dermatology·2026

Cherry Angiomas in Individuals With Neurofibromatosis Type 1.

JAMA dermatology·2026

Risk Stratification Models for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant.

JAMA dermatology·2026

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.

JAMA dermatology·2026

Evaluation of a One-Step Serological Test for Lyme Disease.

The journal of applied laboratory medicine·2026

Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens.

The Journal of clinical investigation·2026

Comparison Between Colorimetric and Subjective Evaluation of Intradermally Injected Histamine-Induced Erythema in Healthy Dogs.

Veterinary dermatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us